Clinical trials: sponsored by Peking University
Hormone Refractory Prostate Cancer
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.
- Trial name
- NCT02867345
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Where
- China
- Sponsor
- Peking University
B-cell Lymphoma
Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
This is a single arm, open-label, one center, dose escalation clinical study to determine the safety and efficacy of infusion of autologous T cells expressing CD19-redirected Chimeric Antigen Receptor (CD19 CAR T) in adult…
- Trial name
- NCT02842138
- Testing
- autologous anti-CD19 CAR T cells
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University
Stomach Neoplasm
The Origin of Infrapyloric Artery
Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies.
- Trial name
- IPA-Origin (NCT03071237)
- Testing
- Gastrectomy
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Peking University
Esophageal Squamous Cell Carcinoma
Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)
This is an open-label phase II trial investigating the effect of metformin in combined with cisplatin plus paclitaxel as neoadjuvant therapy with advanced esophageal squamous cell carcinoma.
- Trial name
- ECMTPneo (NCT03833466)
- Testing
- metformin and chemotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University
Complication, Anastomotic Leak
Prediction of Abdominal Complications After GastroEnterological Surgery
The aim of this multi-centered study is to understand the epidemiology of infectious complications after gastrointestinal surgery in China.
- Conditions
- Complication, Anastomotic Leak, Gastrointestinal Cancer
- Trial name
- PACAGE (NCT03828266)
- Testing
- No intervention
- Where
- 19 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Peking University
Invasive Breast Cancer
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
This is a prospective, single-center, non-randomized, non-controlled study. The estrogen receptor (ER), progesterone receptor (PgR), HER2 status and Ki67 index of CNB specimen are critical biomarkers for making neoadjuvant…
- Trial name
- NCT02773784
- Testing
- immunohistochemistry and/or FISH
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Peking University
Breastcancer
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer who were treated with intensive chemotherapy for prevention of neutrophil reduction.
- Trial name
- NCT02944604
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University
Menorrhagia
Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing
The purpose of the study is to estimate the prevalence of heavy menstrual bleeding (HMB) in females aged between 18 and 50 years old living in Bejing.
- Trial name
- NCT02304510
- Where
- China
- Volunteers
- 2,455 people
- Sponsor
- Peking University
NK/T-cell Lymphoma
PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma
This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8…
- Trial name
- NCT03701022
- Testing
- SHR1210
- Volunteers
- 61 people
- Sponsor
- Peking University
Gastric Cancer
A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy
The purpose of the study is to evaluate the safety and efficacy of laparoscopic distal D2 gastrectomy (LDG) compared with open surgery (ODG) for resectable gastric cancer, to determine whether LDG can be a test arm for a future…
- Trial name
- REALIZATION (NCT02404753)
- Testing
- Neoadjuvant Chemotherapy, Laparoscopic gastrectomy, Open gastrectomy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking University
Advanced Gastric Cancer
Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients
Gastric cancer is one of the most common malignant tumors worldwide. With the rapid aging of global population, the number of elderly patients with local advanced gastric cancer is increasing.
- Trial name
- NCT03564834
- Testing
- Laparoscopic gastrectomy, Open gastrectomy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University
Experimental Tumor
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial
- Trial name
- NCT03617432
- Testing
- Chidamide, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Peking University
Pancreatic Cancer
Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer
This is a randomized phase II trial comparing the first-line treatment with nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in…
- Trial name
- ASAGPAC (NCT03636308)
- Testing
- nanoparticle albumin-bound paclitaxel, S1, Gemcitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Experimental Tumor
Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial
- Trial name
- NCT03611231
- Testing
- Chidamide
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Peking University
Lymphoma
Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
This is a retrospective, single-center, non-randomized, non-controlled study. This study aims to explore the effect of T-lymphocyte subsets changes in immunologic reconstitution and prognosis in lymphoma patients who were treated…
- Trial name
- NCT03283111
- Testing
- autologous stem cell transplantation
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University
Solid Tumor
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors
This is a molecular epidemiological investigation aiming to identify microsatellite instability status from circulating tumor DNA in Chinese patients with refractory advanced solid tumors.
- Trial name
- IMPACT (NCT03596593)
- Testing
- SPANOM (identifying MSI status from ctDNA)
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Peking University
Gastric Cancer
Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer
To explore whether adding olanzapine to paclitaxel chemotherapy could improve chemotherapy tolerance and improve patient quality of life and prolong treatment failure time (TTF) in advanced gastric cancer after failure of…
- Trial name
- NCT03575637
- Testing
- Olanzapine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University
mCRC
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study. The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal…
- Trial name
- NCT03567629
- Testing
- Irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University
Gastric Cancer, Neoadjuvant Chemotherapy
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Based on multiple studies, the immune (systemic inflammation) and nutrition index were correlated with short- and long-term prognosis for gastric cancer.
- Conditions
- Gastric Cancer, Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, Systemic Inflammatory Response Syndrome (SIRS)
- Trial name
- NCT03493880
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
GIST
To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.
To compare the efficacy of surgery followed by sunitinib with surgery followed by imatinib in GIST patients with progression on imatinib;To investigate the optimal therapy after surgery in GIST patients with focal or multifocal…
- Trial name
- NCT03424876
- Testing
- Imatinib 400mg, Sunitinib 37.5Mg Oral Capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University